🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06524388
Enrolling by invitation Not applicable

Adaptive Cognitive Training on Cognitive Function in Elderly Diabetes Patients in the Community

NCT06524388 · tracked via the Priya Life Science China tracker
Sponsor
Fanfan Zheng
Phase
Not applicable
Started
2024-10-29
Last updated
2025-12-04

Condition(s) studied

CognitionDiabetes Mellitus, Type 2Aging

Investigational drug(s) / intervention(s)

adaptive cognitive trainingplacebo cognitive training

adaptive cognitive training: The intervention was computerized, multi-domain, adaptive cognitive training. Training areas include processing speed, attention, perception, long-term memory, working memory, computation, executive control, reasoning, and problem-solving. Embedded in the Adaptive Cognitive training application is an adaptive algorithm that will help provide each participant with a cognitive training task at the right level of difficulty based on their profile and real-time performance.

placebo cognitive training: Participants received cognitive training tasks of fixed difficulty.

Study summary

Objective A growing body of evidence supports diabetes as a risk factor for cognitive decline. Diabetes is significantly associated with accelerated cognitive decline, poorer cognitive function, and mild cognitive impairment and dementia. Cognitive training is an effective intervention to improve cognitive function. However, the current cognitive training does not fully consider the different areas and degrees of cognitive function impairment of older adults. This study aims to evaluate the effect of adaptive cognitive training on cognitive function of older adults with hypertension in the community.

Participants Age 60 years or older, diagnosis of diabetes, fasting blood glucose≥6.1mmol/L and cognitive function assessment showed no dementia.

Design The study was designed as a double-blind randomized controlled trial. 120 diabetes participants without dementia aged 60 years or older in Shijingshan, Beijing and Haidian, Beijing were included. Participants will be randomized to adaptive cognitive training (intervention group) and placebo cognitive training (control group) at a ratio of 1:1. Both training will be delivered by using PADs with the same appearance. The interventions will last for 6 months and follow up to 12 months, and both groups will be followed up on the same time schedules for all outcome measurements. The primary outcome is changes in MoCA scores from baseline to post-intervention, 6 months. The current trial has been reviewed by the Ethics Committee of Plastic Surgery Hospital, Chinese Academy of Medical Sciences \& Peking Union Medical College (approval number: 2024-162).

Eligibility

Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * with a clear diagnosis of diabetes (according to ICD-10 or DSM-criteria), fasting blood glucose≥6.1mmol/L, maintaining the original diabetes treatment strategy * age ≥60 years old * literate and able to use smart phone or tablet computer skillfully, with CAIDE dementia risk score \>9, but without a diagnosis of dementia (ICD-10 or DSM-dementia diagnostic criteria) * have lived in the target community for at least 6 months and continue to live in the original community for the next 12 months Exclusion Criteria: * Stroke or brain surgery in the previous 12 months * Alcohol or drug abuse in the past 12 months * Families, important people of participants in the study have concerns * Live in the same household as a participant who has been randomly assigned * Severe aphasia, physical disability, or any other factor that may prevent completion of neuropsychological testing * Use of medications that may affect cognition, including sedatives, anxiolytics, hypnotics, nootropics, and cholinergic drugs; Refusing or not receiving cognitive training * currently participating in another clinical trial.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Xihuangcun Hospital Beijing China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06524388 on ClinicalTrials.gov ↗ ← All trials in China